Why Accelerate Progress

About Us

Why Accelerate Progress?

The substantial progress that has been made in our fundamental understanding in the biology of the many diseases we call “cancer”, since the signing of the National Cancer Act in 1971, can only benefit the cancer patient if we have policies that fully address the challenge.  These must include systems of discovery, development, and regulatory approval that provide for the efficient translations of advances in laboratory research into a public benefit in a timely manner.  Failures to provide efficient systems for new therapy review and approval, and funding for other important initiatives such as Critical Path, contribute directly to suffering and deaths from cancer and other life-threatening diseases. The economic consequences in the form of increased costs of care and lost productivity are enormous and often unrecognized or under-reported.  Recognizing that cancer is the second leading cause of death in the United States, a humane society ought to find such system failures intolerable.

The tremendous promise of Accelerated Approval and Fast Track initiatives, passed by Congress in the Food and Drug Administration Modernization Act of 1997 ("FDAMA"), has remained largely unrealized by patients suffering from cancer and other life-threatening diseases.  In a time when a move towards increasingly personalized approaches to treatment requires an increased number of therapeutic options to be available for patients and doctors to choose from, the trend in new approvals is down and continuing to slow.  The status quo can not support the potential that personalized medicine holds.  We must make meaningful changes and improvements to the systems governing these issues if we are to make real progress on behalf of the patients in need. 

Beyond cancer, there are many fighting disease who face the same system barriers to progress.  Amazing work and research is being done to fight Parkinson’s diseases, Huntington’s, ALS, Alzheimer’s, Diabetes, and scores of other life-threatening or life-stealing diseases.  Our work to accelerate progress will improve the system for all researchers and fighters against disease.  Creating a more efficient, more thoughtful system benefits everyone in the system and every ‘customer’ of the system, which are the patients.  Advancing ‘accelerating science’ like adaptive trial design, Bayesian analyses, biomarker identification and validation, greater network sharing, etc. allows more researchers to design and implement better trials to be able to learn more, more quickly, accelerating the learning and feedback loop that results in greater knowledge, delivering greater progress for patients in less time at lower cost. 

For more on the Why and How of Accelerate Progress, click this link.